Company intelligence / Profile preview

Pevion Biotech AG

Ownership: Private
Development stage: Other

Overview

Pevion’s virosome-based vaccines demonstrated robust immunogenicity and safety profiles in early-stage human trials. The PEV7 therapeutic Candida vaccine showed high mucosal immune response rates in Phase II studies. The malaria vaccine candidate was considered highly promising based on strong immunogenicity data from human trials before being acquired by Mymetics Corporation.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Vaccines (prophylactic and therapeutic)Virosome-based vaccinesProtein antigensImmunostimulants
Industry: Biotech

Drug pipeline

8 assets

PEV3A

7 more assets in the full pipeline.

Partnerships

Cevec Pharmaceuticals—exclusive license for CAP-T protein expression technology for infectious disease vaccines.Mymetics Corporation—collaboration/outlicensing of malaria program; also licensed HIV virosomal technology from Pevion.

Beyond the preview

Go deeper on Pevion Biotech AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pevion Biotech AG.